25 Years of Proton Pump Inhibitors: A Comprehensive Review
Gut and Liver
;
: 27-37, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-100547
ABSTRACT
Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease. Despite their overall efficacy, PPIs do have some limitations related to their short plasma half-lives and requirement for meal-associated dosing, which can lead to breakthrough symptoms in some individuals, especially at night. Longer-acting PPIs and technology to prolong conventional PPI activity have been developed to specifically address these limitations and may improve clinical outcomes.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Úlcera Péptica
/
Plasma
/
Protones
/
United States Food and Drug Administration
/
Farmacocinética
/
Reflujo Gastroesofágico
/
Bombas de Protones
/
Inhibidores de la Bomba de Protones
/
Rabeprazol
/
Metabolismo
Idioma:
Inglés
Revista:
Gut and Liver
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS